We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
Read MoreHide Full Article
Key Takeaways
argenx shares fell 12% after an interim analysis found its UNITY study could not meet the primary endpoint.
The IDMC recommended stopping the phase III trial of efgartigimod SC in adults with Sjogren's disease.
FB102 met its primary endpoint in celiac disease, supporting argenx's plans to advance the candidate further.
argenx (ARGX - Free Report) suffered a clinical setback after deciding to discontinue the late-stage UNITY study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren’s disease.
The decision follows a recommendation from an Independent Data Monitoring Committee (“IDMC”) to stop the study for futility after an interim analysis showed that the trial was unable to meet its primary endpoint.
Shares of the company were down 12% following the announcement.
The development is a setback for argenx’s efforts to expand its immunology pipeline into Sjögren’s disease, a chronic systemic autoimmune condition characterized by symptoms such as dry eyes, dry mouth, fatigue and joint pain. The disease can significantly affect patients’ quality of life, and treatment options remain limited.
Year to date, ARGX’s shares have lost 2.7% against the industry’s 0.6% growth.
Image Source: Zacks Investment Research
More on ARGX’s UNITY Study
The UNITY study was a randomized, double-blind, placebo-controlled phase III trial designed to evaluate the efficacy, safety and tolerability of efgartigimod SC in adults with moderate-to-severe Sjögren’s disease.
Patients received weekly efgartigimod SC or placebo alongside stable background standard-of-care treatment. The primary endpoint was the change from baseline in systemic disease activity, measured using the clinical EULAR Sjögren’s Syndrome Disease Activity Index (clinESSDAI), at week 48.
Key secondary endpoints included the proportion of patients achieving low disease activity, response rates measured using the Sjögren’s Tool for Assessing Response (“STAR”), changes in patient-reported symptoms and safety outcomes.
However, the IDMC concluded that the study could not meet its primary endpoint, prompting ARGX to discontinue the trial.
Following the study’s closure and database lock, argenx plans to conduct a comprehensive analysis of the results to better understand the outcome and identify insights that could inform future research into Sjögren’s disease.
We note that argenx has an established commercial presence with its Vyvgart franchise. Vyvgart (efgartigimod alfa-fcab) is a first-in-class human IgG1 antibody fragment that binds to the neonatal Fc receptor, reducing circulating IgG autoantibodies.
Vyvgart is approved for generalized myasthenia gravis (gMG), while Vyvgart Hytrulo, its subcutaneous formulation, is approved for gMG and chronic inflammatory demyelinating polyneuropathy. Vyvgart is also approved for immune thrombocytopenia in Japan.
While these approved indications provide an established foundation for the franchise, the discontinuation of the UNITY study represents a setback to its potential expansion into Sjögren’s disease. The decision limits the drug’s prospects in this indication and highlights the clinical risks associated with pipeline expansion.
The company generated $1.5 billion in global product net sales in the second quarter of 2026, representing 17% quarter-over-quarter growth and a year-over-year increase of 60% or $0.6 billion.
The news overshadowed ARGX’s announcement of positive data from another study.
ARGX announced that the phase II study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease, met its primary endpoint. Patients treated with FB102 demonstrated a statistically significant and clinically relevant treatment effect compared to placebo. The company believes the results support advancing FB102 into phase III development.
ARGX Zacks Rank and Stocks to Consider
argenx currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Alnylam Pharmaceuticals (ALNY - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and CRISPR Therapeutics (CRSP - Free Report) and Aldeyra Therapeutics (ALDX), each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Alnylam’s 2026 earnings per share have decreased from $8.65 to $8.63. Over the same period, earnings estimates for 2027 have decreased from $12.13 to $12.04.
Alnylam’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 27.58%.
Over the past 60 days, estimates for CRISPR Therapeutics’ 2026 loss per share have decreased to $4.47 from $4.53. Over the same period, earnings estimates for 2027 have decreased to $3.61 from $3.63.
CRISPR Therapeutics’ earnings beat estimates in two of the trailing four quarters and missed on the remaining two occasions, with the average negative surprise being 1.38%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
View the Zacks #1 Rank List
Image: Bigstock
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
Key Takeaways
argenx (ARGX - Free Report) suffered a clinical setback after deciding to discontinue the late-stage UNITY study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren’s disease.
The decision follows a recommendation from an Independent Data Monitoring Committee (“IDMC”) to stop the study for futility after an interim analysis showed that the trial was unable to meet its primary endpoint.
Shares of the company were down 12% following the announcement.
The development is a setback for argenx’s efforts to expand its immunology pipeline into Sjögren’s disease, a chronic systemic autoimmune condition characterized by symptoms such as dry eyes, dry mouth, fatigue and joint pain. The disease can significantly affect patients’ quality of life, and treatment options remain limited.
Year to date, ARGX’s shares have lost 2.7% against the industry’s 0.6% growth.
Image Source: Zacks Investment Research
More on ARGX’s UNITY Study
The UNITY study was a randomized, double-blind, placebo-controlled phase III trial designed to evaluate the efficacy, safety and tolerability of efgartigimod SC in adults with moderate-to-severe Sjögren’s disease.
Patients received weekly efgartigimod SC or placebo alongside stable background standard-of-care treatment. The primary endpoint was the change from baseline in systemic disease activity, measured using the clinical EULAR Sjögren’s Syndrome Disease Activity Index (clinESSDAI), at week 48.
Key secondary endpoints included the proportion of patients achieving low disease activity, response rates measured using the Sjögren’s Tool for Assessing Response (“STAR”), changes in patient-reported symptoms and safety outcomes.
However, the IDMC concluded that the study could not meet its primary endpoint, prompting ARGX to discontinue the trial.
Following the study’s closure and database lock, argenx plans to conduct a comprehensive analysis of the results to better understand the outcome and identify insights that could inform future research into Sjögren’s disease.
We note that argenx has an established commercial presence with its Vyvgart franchise. Vyvgart (efgartigimod alfa-fcab) is a first-in-class human IgG1 antibody fragment that binds to the neonatal Fc receptor, reducing circulating IgG autoantibodies.
Vyvgart is approved for generalized myasthenia gravis (gMG), while Vyvgart Hytrulo, its subcutaneous formulation, is approved for gMG and chronic inflammatory demyelinating polyneuropathy. Vyvgart is also approved for immune thrombocytopenia in Japan.
While these approved indications provide an established foundation for the franchise, the discontinuation of the UNITY study represents a setback to its potential expansion into Sjögren’s disease. The decision limits the drug’s prospects in this indication and highlights the clinical risks associated with pipeline expansion.
The company generated $1.5 billion in global product net sales in the second quarter of 2026, representing 17% quarter-over-quarter growth and a year-over-year increase of 60% or $0.6 billion.
The news overshadowed ARGX’s announcement of positive data from another study.
ARGX announced that the phase II study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease, met its primary endpoint. Patients treated with FB102 demonstrated a statistically significant and clinically relevant treatment effect compared to placebo. The company believes the results support advancing FB102 into phase III development.
ARGX Zacks Rank and Stocks to Consider
argenx currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Alnylam Pharmaceuticals (ALNY - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and CRISPR Therapeutics (CRSP - Free Report) and Aldeyra Therapeutics (ALDX), each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Alnylam’s 2026 earnings per share have decreased from $8.65 to $8.63. Over the same period, earnings estimates for 2027 have decreased from $12.13 to $12.04.
Alnylam’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 27.58%.
Over the past 60 days, estimates for CRISPR Therapeutics’ 2026 loss per share have decreased to $4.47 from $4.53. Over the same period, earnings estimates for 2027 have decreased to $3.61 from $3.63.
CRISPR Therapeutics’ earnings beat estimates in two of the trailing four quarters and missed on the remaining two occasions, with the average negative surprise being 1.38%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.